Sep 01,2020

Blue Note Therapeutics Enters Agreement to Create a Prescription Digital Therapeutic Medical Device for Cancer Patients

Memorial Sloan Kettering Cancer Center (MSK) and Blue Note Therapeutics, Inc. have agreed to collaborate on creating a prescription digital therapeutic medical device from a psychological intervention created specifically for cancer patients with advanced cancer. MCP is a brief, manualized psychotherapeutic intervention to help patients suffering with loss of meaning around illness.

COLLABORATION PARTNERSHIP

#r&d

#pdt

View Analyst & Ambassador Comments
Go to original news
Oct 01,2020

Blue Note Therapeutics Enters Licensing Agreement with Massachusetts General Hospital for Digital Therapeutic for Acute Myeloid Leukemia Patients

Blue Note Therapeutics, Inc., a prescription digital therapeutics company, has entered into a licensing agreement with Massachusetts General Hospital (MGH) to further develop and commercialize a digital therapeutic prototype created specifically for patients with acute myeloid leukemia by researchers from the MGH Cancer Outcomes Research and Education Program. A randomized head-to-head clinical trial is currently underway at MGH and Dana-Farber Cancer Institute to measure the prototype’s ability to improve the physical and psychological symptoms patients with acute myeloid leukemia experience during hospitalization for their leukemia care as compared to usual care.

COLLABORATION PARTNERSHIP

#r&d

View Analyst & Ambassador Comments
Go to original news
Nov 16,2020

Voluntis Receives CE Mark for Oleena, Key Milestone to the Future Commercialization of Its Digital Therapeutics for Oncology

Voluntis, a leader in digital therapeutics, today announced that it has received the CE mark for Oleena. Oleena is Voluntis’ proprietary digital therapeutic that enables patients to self-manage symptoms across a wide range of cancer therapies, and also allows care teams to remotely monitor patients. Oleena is based on Voluntis’ Theraxium platform, and its patented algorithm engine, which also serves as the foundation for digital therapeutics the company co-develops with life science partners.

REGULATORY CE MARK

#mobile app

#rpm

View Analyst & Ambassador Comments
Go to original news
Dec 08,2020

Kaiku Health to present research at ESMO Immuno-Oncology Congress 2020

Kaiku Health, together with Oulu University Hospital, will present research at the ESMO Immuno-Oncology Congress 2020, which takes place as a virtual conference this year. The research investigates the use of Machine Learning to predict the objective response rate in immune checkpoint inhibitor treated patients when patient-reported and clinical data data are used as input for the Machine Learning based model.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Dec 18,2019

Voluntis announces new pharma collaboration in oncology

Voluntis, a leader in digital therapeutics, announced today a collaboration with Novartis to evaluate the use of Voluntis’ digital therapeutic platform for Breast Cancer patients with the goal to empower patients with tools to more effectively manage symptoms and, thereby, improve patient experience and outcomes. This collaboration will leverage Voluntis’ Theraxium Oncology, the company’s core platform for digital therapeutics in the field of oncology.

COLLABORATION PARTNERSHIP

#r&d

#software

#rpm

View Analyst & Ambassador Comments
Go to original news
Jul 02,2019

Voluntis maintains a strong and promising view for the company’s future

Voluntis, a company specializing in digital therapeutics, takes a look at the latest developments in the first half of 2019 and confirms its roadmap. “During the first half of the year, we actively pursued the deployment of our diabetes solutions and the development of our oncology platform. Voluntis’ market momentum is positive and its product portfolio is expanding. The strategic value of our digital therapeutics, particularly in the United States, has been gaining traction.” said Pierre Leurent, CEO of Voluntis. In oncology, Voluntis has finalized the development of its multicancer symptom management solution and reaffirms its ambition to be able to launch its product in the second half of 2019.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Jul 31,2019

Voluntis announces market authorization for Oleena™, first digital therapeutic in oncology

Voluntis, a leader in digital therapeutics, today announced it has successfully completed a U.S. Food and Drug Administration (FDA) regulatory review of its Oleena™ software for oncology-related symptoms management and remote patient monitoring. Oleena™ is determined as Class II medical device falling under enforcement discretion per FDA Guidance. Oleena™ is a care companion for the cancer patient journey based on mobile and web technologies that enables self-management of symptoms and remote monitoring by care teams.

REGULATORY FDA

#mobile app

#rpm

View Analyst & Ambassador Comments
Go to original news
Mar 20,2019

Voluntis announces end of Roche Pharma France collaboration for Zemy solution

Voluntis (Euronext Paris, Ticker: VTX – ISIN: FR0004183960), a company specializing in digital therapeutics, announces Roche Pharma France’s decision not to pursue ZEMY’s development in breast cancer. The collaboration between Roche Pharma France and Voluntis on this project will end at the conclusion of the feasibility clinical study currently being conducted by Roche Pharma France, end of April 2019. The contract between Roche Pharma France and Voluntis, signed in October 2015, aimed to develop and distribute the ZEMY solution in breast cancer, based on the Theraxium Oncology platform.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Sep 30,2019

Voluntis reports business review and financial results for the first half of 2019

Voluntis, a leader in digital therapeutics, today released its first half of 2019 financial results and business highlights. The first half of 2019, Voluntis generated revenue of €2.0 million compared with €2.2 million for the same period in 2018. The Group is still in a transition phase towards a turnover that consists more of recurring revenues related to the marketing of its products than of pre-launch revenues related to product development and approval.

View Analyst & Ambassador Comments
Go to original news
Jan 17,2019

Proteus' digital pill is now delivering chemotherapy

In conjunction with Fairview Health Services and University of Minnesota Health, Proteus Digital Health unveiled plans to pair its sensor-equipped digital pills with an oral oncology therapeutic. According to an announcement from Proteus, the new care model is currently being used to treat stage 3 and stage 4 colorectal cancer patients receiving care at Fairview. There, clinicians are prescribing “digital capecitabine,” which consists of the ingestible sensor, the accompanying mobile data platform and the established chemotherapy medication.

PRODUCT

#pdt

#connected device

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY